ICU Medical (ICUI) Expected to Announce Earnings on Thursday

ICU Medical (NASDAQ:ICUI - Get Free Report) is projected to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of $1.48 per share and revenue of $599.10 million for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.

ICU Medical Stock Down 3.5 %

NASDAQ ICUI traded down $5.73 during trading on Friday, reaching $157.42. 159,367 shares of the company's stock were exchanged, compared to its average volume of 190,778. The company has a 50 day moving average price of $160.74 and a two-hundred day moving average price of $165.62. The stock has a market cap of $3.85 billion, a P/E ratio of -34.45 and a beta of 0.63. ICU Medical has a 1 year low of $93.36 and a 1 year high of $196.26. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the business's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $162.91, for a total value of $1,954,920.00. Following the transaction, the chief executive officer now directly owns 104,593 shares of the company's stock, valued at approximately $17,039,245.63. The trade was a 10.29 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Christian B. Voigtlander sold 1,430 shares of the company's stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $158.00, for a total transaction of $225,940.00. The disclosure for this sale can be found here. Insiders sold a total of 17,737 shares of company stock valued at $2,879,752 in the last ninety days. Insiders own 6.70% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ICUI. Needham & Company LLC restated a "hold" rating on shares of ICU Medical in a research note on Wednesday, November 13th. StockNews.com upgraded shares of ICU Medical from a "hold" rating to a "buy" rating in a report on Wednesday, November 20th. KeyCorp increased their target price on shares of ICU Medical from $198.00 to $209.00 and gave the company an "overweight" rating in a research report on Wednesday, November 13th. Finally, Jefferies Financial Group raised shares of ICU Medical from a "hold" rating to a "buy" rating and set a $200.00 price target for the company in a research report on Wednesday, December 11th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $199.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.